HBK Sorce Advisory LLC Buys 16,288 Shares of Agenus Inc. (NASDAQ:AGEN)

HBK Sorce Advisory LLC boosted its stake in Agenus Inc. (NASDAQ:AGEN – Get Rating) by 100.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,576 shares of the biotechnology company’s stock after purchasing an additional 16,288 shares during the period. HBK Sorce Advisory LLC’s holdings in Agenus were worth $38,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Lazard Asset Management LLC boosted its holdings in shares of Agenus by 1,321.3% during the 3rd quarter. Lazard Asset Management LLC now owns 1,153,038 shares of the biotechnology company’s stock valued at $2,363,000 after acquiring an additional 1,071,912 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Agenus during the third quarter valued at about $157,000. AE Wealth Management LLC bought a new stake in shares of Agenus during the fourth quarter worth about $36,000. Lynch & Associates IN grew its holdings in shares of Agenus by 62.3% during the fourth quarter. Lynch & Associates IN now owns 45,580 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Los Angeles Capital Management LLC increased its stake in shares of Agenus by 32.3% in the third quarter. Los Angeles Capital Management LLC now owns 1,092,218 shares of the biotechnology company’s stock valued at $2,239,000 after buying an additional 266,467 shares during the period. Institutional investors and hedge funds own 53.81% of the company’s stock.

Agenus Stock Down 1.4 %

NASDAQ AGEN opened at $1.40 on Friday. Agenus Inc. has a 52 week low of $1.25 and a 52 week high of $3.37. The business has a 50 day moving average price of $1.55 and a 200-day moving average price of $2.15. The company has a market cap of $488.43 million, a price-to-earnings ratio of -1.71 and a beta of 1.43.

Agenus (NASDAQ:AGEN – Get Rating) last issued its quarterly earnings data on Tuesday, March 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). Agenus had a negative net margin of 264.19% and a negative return on equity of 1,159.04%. The business had revenue of $28.39 million for the quarter, compared to analyst estimates of $17.83 million. On average, equities research analysts anticipate that Agenus Inc. will post -0.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. EF Hutton Acquisition Co. I reiterated a “buy” rating and set a $8.30 price target on shares of Agenus in a report on Tuesday, March 28th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Agenus in a research note on Tuesday, February 28th. B. Riley reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Agenus in a research note on Wednesday, March 29th. Finally, StockNews.com assumed coverage on shares of Agenus in a research report on Thursday. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.33.

Insider Activity at Agenus

In other news, major shareholder Agenus Inc bought 100,200 shares of the stock in a transaction dated Friday, May 5th. The stock was bought at an average price of $0.95 per share, for a total transaction of $95,190.00. Following the completion of the acquisition, the insider now directly owns 21,595,047 shares in the company, valued at approximately $20,515,294.65. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have purchased a total of 250,954 shares of company stock valued at $267,492 over the last 90 days. Insiders own 4.80% of the company’s stock.

Agenus Profile

(Get Rating)

Agenus, Inc is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K.